Infectious Diseases Company Featured on March 9th and 10th, 2009, at BioSquare Meeting in France, and March 17, 2009, at BioEurope in Italy
ROCKVILLE, Md., March 3 /PRNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products for infectious diseases of epidemic potential has announced that Alan Klein, Sequella Executive Vice President for Corporate Development, will participate in a Panel at the BioSquare 2009 Meeting at the Lyon Congress Center in Lyon, France. The Panel, entitled New Antibiotherapies for Tomorrow, will be held from 10:45 AM to 12:00 noon on March 9, 2009. The presentation will address antibiotic strategies of the 21st century and highlights both the most advanced and successful approaches and the characteristics of future opportunities.
Mr. Klein will also present at the same meeting on Tuesday, March 10, from 10:15 to 11:00 AM in Room St. Clair 2, 2nd floor, as part of the CNS & Infectious Diseases section of BioSquare 2009 at the Lyon Congress Center in Lyon, France.
Sequella will also present on March 17, 2009 at 5:00 PM in Room Yellow 3, Level 1, of the Infectious Diseases section at BioEurope Spring 2009 at the Milano Convention Centre in Milan, Italy.
"We look forward to participating in both of these European conferences and presenting new information regarding the progress of our product portfolio, while continuing partnership discussions that will appropriately monetize our assets," said Mr. Klein. To learn more about Sequella or their presentations at BioSquare or the BioEurope Spring conference, visit www.sequella.com.
Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatments for infectious diseases of epidemic potential. The company leverages its global influence, R&D platforms and infectious disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat global health threats with significant market opportunity.
This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Sequella disclaims any intent or obligation to update forward-looking statements, except as required by law.
|SOURCE Sequella, Inc.|
Copyright©2009 PR Newswire.
All rights reserved